A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Study Identifier
MAF/AGN/OPH/GLA/025
CT.gov Identifier
NCT01632423
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Glaucoma - Open Angle
  • Ocular Hypertension
    • Study Drug
  • bimatoprost 0.01%
    • Phase
    N/A
    Sex
    Female & Male
    Age
    N/A
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Diagnosed with primary open angle glaucoma or ocular hypertension * Prescribed Lumigan®
    Exclusion Criteria:
    * None

    Protocol Summary

    This is an observational study of Lumigan® 0.01% (bimatoprost) treatment in clinical practice for patients with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).

    Study Locations

    Location
    Status
    Location
    Berlin, Germany
    Status
    Not applicable